Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer

Niclosamide has preclinical activity against a wide range of cancers. In prostate cancer, it inhibits androgen receptor variant 7 and synergizes with abiraterone. The approved niclosamide formulation has poor oral bioavailability. The primary objective of this phase Ib trial was to identify a maximu...

Descripción completa

Detalles Bibliográficos
Autores principales: Parikh, Mamta, Liu, Chengfei, Wu, Chun-Yi, Evans, Christopher P., Dall’Era, Marc, Robles, Daniel, Lara, Primo N., Agarwal, Neeraj, Gao, Allen C., Pan, Chong-Xian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973745/
https://www.ncbi.nlm.nih.gov/pubmed/33737681
http://dx.doi.org/10.1038/s41598-021-85969-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973745/
https://www.ncbi.nlm.nih.gov/pubmed/33737681
http://dx.doi.org/10.1038/s41598-021-85969-x

Ejemplares similares